JAMA/ LinkedIn
Sep 1, 2025, 07:40
JAMA: Semaglutide and Tirzepatide Reduce Heart Failure Risk in Patients With HFpEF
Journal of the American Medical Association (JAMA) made a noteworthy post on LinkedIn:
“In patients with cardiometabolic HFpEF, semaglutide and tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but tirzepatide offered no additional benefit over semaglutide.”
Read the full article here:
Article: Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Authors: Nils Krüger, Sebastian Schneeweiss, Kenshiro Fuse, Sofiya Matseyko, Sushama Kattinakere Sreedhara, Georg Hahn, Heribert Schunkert, Shirley V. Wang
Follow the newest insights in hematology with Hemostasis Today.
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH
-
Sep 9, 2026, 16:07Zahra Safarzadeh: From Novel F8 Variant to Clinical Significance
-
Sep 9, 2026, 16:00Maximo Agustin Schiavone: HDL Beyond Cholesterol – Linking Lipids and Immunity
-
Sep 9, 2026, 15:56Abdul Mannan: When Antiseizure Drugs Alter DOAC Risk